Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Opicapone in Parkinson's Disease
NCT03496870Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by Neurocrine Biosciences. Primary endpoints: Area under the curve (AUC 0-24) of opicapone and its metabolites up to 19 days, Area under the curve (AUC 0-tlast) of opicapone and its metabolites up to 19 days and 4 more. Started Feb 2018; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03496870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496870.